Navigation Links
Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
Date:4/14/2008

ollaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other risk factors are discussed under "Risk Factors" in Kosan's Annual Report on Form 10-K for the year ended December 31, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
2. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
3. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
8. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
11. Metabolex Initiates Phase 1 Trial of MBX-2982
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... KVISTGARD, Denmark, December 1 /PRNewswire-First...in 2007 with the intent to procure an MVA-based,...d Government Services,Canada, on behalf of the Ca...,a contract to Bavarian Nordic for the delivery o...ntend to use IMVAMUNE(R) as part of the,country,s...
(Date:12/1/2008)...LANTA, Dec. 1 GeoVax Lab...sed biotechnology company developing,human vaccin...iency Virus) and,other infectious agents, announc...ccine Trials will take place in twelve sites acros...cted in collaboration with The National Institutes...
(Date:11/30/2008)..., , CHICAGO, Dec. 1 /PRNewswire-USNewswire/ ...sed cerebral blood flow and a greater number of sm...ngs presented today at the annual meeting of the R... , The study, conducted at the University of ...t to compare brain scans of older adults who exerc...
(Date:11/28/2008)... GÿRLITZ, Germany, November 28 G...bal leadership in specialized HIV monitoring and,...and emerging countries. In,the year 2008, 2.5 mil...ortable, robust and highly affordable "CyFlow" sys...e living with HIV/AIDS. Due to introduction of the...
Breaking Medicine Technology:The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline 28KW 6002 29 3577 1Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline 28KW 6002 29 3577 2Influenza Vaccination Rates Among Health Care Personnel Remain Well Below National Goal 1438 1Influenza Vaccination Rates Among Health Care Personnel Remain Well Below National Goal 1438 2Influenza Vaccination Rates Among Health Care Personnel Remain Well Below National Goal 1438 3M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates 2338 1M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates 2338 22 faced particles act like tiny submarines 3574 12 faced particles act like tiny submarines 3574 2
(Date:12/1/2008)...irstCall/ -- Pressure BioSciences, Inc. (Nasdaq: ... comprehensive restructuring program designed to s...ons, and refocus the Company,s business strategy i... found significant market acceptance. The restruc... in personnel of eight full-time employees (40% of...
(Date:12/1/2008)... other special needs, report shows , , M...stic children are more likely to see their sons or...overnment report shows. , Data from the Nation...ds also indicated that when compared with familie...hysical needs, parents caring for autistic childre...
(Date:12/1/2008)...)Concerned that the global financial crisis will l...countries, leaders of the world,s largest agricult...elatively modest, well-targeted investments could ...ons of people living on less than $1 a day. , Sp...roup on International Agricultural Research (CGIAR...
(Date:12/1/2008)...oi:10.1016/j.clim.2008.07.027) published by Elsevi...al journal of the Clinical Immunology Society (CIS...uction of a specific type of immune suppressive ce...se. These immune suppressive cells show great pote... improving transplantation outcomes. , Immunot...
Breaking Medicine News(10 mins):Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7Health News:Health Needs of Autistic Children Often Unmet 2Health News:Health Needs of Autistic Children Often Unmet 3Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 2Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 3Health News:Experts: Targeted agricultural investments will yield high results, slash poverty in Africa 4
...ngly certain that the bird flu virus H5N1 will at ...ans , the only uncertainty //being "when?" This wo...d create a scenario like a science fiction film. ...mans got infected through birds, and 148 deaths. ...
...gly, criticized the practice of using duct tape a ...tive lumpy warts //which crop up on skin of hands ...esearchers gathered data which disproves the popul...helpful in some way to hinder the growth of warts ...
...entists, mild electric stimulation of the brain wh... neuroscientist at the University //of Lübeck , Ge...y applied currents that mimic natural slow oscilla...attached to the scalp. 13 medical students who we...
... States, 23.5 million children travel billions of ...or Injury Research and Policy (CIRP) at Columbus//...l sample to describe nonfatal school bus-related i...d in hospital emergency departments across the cou...
Other Medicine News:Health News:Human Strain Of Bird Flu Virus, Just A Matter Of Time? 2Health News:Improved memory with mild electric stimulation 2Health News:Nonfatal School Bus-Related Injuries To Children More Common Than Previously Thought 2
The Finnpipette BioControl multichannel has the same innovative features as the single channel model.The same universal handle fits all seven multichannel and five single channel tip cone modules. Bo
... The new Finnpipette Novus is so user-friendly tha.... With the intuitive instantly familiar menu and s...ing functions you need quickly and easily. The lar...ll names of all functions. The easily accessible ...
...ntire Column of a 384 Well Plate at Once , To inc...es, you need a pipettor that can adapt to the narr...ur 16-channel Impact pipettor., Available with Im...s innovation was specifically designed to allow yo...
The Seal-Away CS and Alliance Catheter Delivery System introducers are designed for the introduction of catheters or devices into the coronary sinus from a superior approach. These introducers combin
Medicine Products: